Replies to post #32 on BridgeBio Pharma Inc (BBIO)

[subslover]

BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events
March 06 2023 - 07:00AM
GlobeNewswire Inc.
https://ih.advfn.com/stock-market/NASDAQ/bridgebio-pharma-BBIO/stock-news/90423204/bridgebio-announces-positive-phase-2-cohort-5-resu